Perjeta regimen may help people with HER2-positive early breast cancer live longer wi
 

New data show that adding the personalised therapy, Perjeta to Herceptin® (trastuzumab) and docetaxel chemotherapy in the neoadjuvant setting (before surgery), may cut the risk of disease...

More...